AbbVie Stock Falls 11% in a Month: Should You Buy the Dip?

AbbVie’s (ABBV) stock declined almost 11% in the past month, mainly due to a recent pipeline setback. In November, AbbVie announced that two registration-enabling phase II studies on emraclidine, its once-daily oral candidate for treating schizophrenia, failed to meet their primary endpoints. Emraclidine was added to AbbVie’s pipeline with this year’s acquisition of Cerevel and was a key reason for AbbVie to buy the company, thus bringing into question the viability of the deal.The failure of the phase II s ...